Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval Summary
Paul G. Kluetz(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), Martin T. Haber(United States Food and Drug Administration), Robert Justice(United States Food and Drug Administration), Shenghui Tang(United States Food and Drug Administration), Eldon E. Leutzinger(United States Food and Drug Administration), Hui Zhang(Shandong University), William F. Pierce(United States Food and Drug Administration), Todd R. Palmby(University of North Carolina at Chapel Hill), Ali Al‐Hakim(Center for Drug Evaluation and Research), Elleni Alebachew(United States Food and Drug Administration), Pengfei Song(Nanyang Technological University), Wei Chen(Zigong First People's Hospital), Qi Liu(Capital Medical University), V. Ellen Maher(United States Food and Drug Administration), Rajeshwari Sridhara(Center for Drug Evaluation and Research), Amna Ibrahim(Beni-Suef University)
Cited by 171
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k